Citigroup’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-53,844
| Closed | -$517K | – | 6103 |
|
|
2024
Q4 | $517K | Buy |
53,844
+3,858
| +8% | +$20.1K | ﹤0.01% | 3801 |
|
|
2024
Q3 | $143K | Buy |
49,986
+34,604
| +225% | +$107K | ﹤0.01% | 4583 |
|
|
2024
Q2 | $44.9K | Buy |
15,382
+2,531
| +20% | +$6.92K | ﹤0.01% | 4649 |
|
|
2024
Q1 | $41K | Buy |
12,851
+3,023
| +31% | +$10.1K | ﹤0.01% | 4718 |
|
|
2023
Q4 | $33K | Buy |
9,828
+8,704
| +774% | +$22.4K | ﹤0.01% | 4733 |
|
|
2023
Q3 | $2.67K | Sell |
1,124
-20,586
| -95% | -$43.1K | ﹤0.01% | 4888 |
|
|
2023
Q2 | $38.2K | Sell |
21,710
-103,329
| -83% | -$264K | ﹤0.01% | 4772 |
|
|
2023
Q1 | $385K | Sell |
125,039
-38,636
| -24% | -$232K | ﹤0.01% | 3310 |
|
|
2022
Q4 | $867K | Buy |
163,675
+160,829
| +5,651% | +$735K | ﹤0.01% | 2743 |
|
|
2022
Q3 | $10K | Buy |
2,846
+1,444
| +103% | +$4.78K | ﹤0.01% | 5005 |
|
|
2022
Q2 | $4K | Sell |
1,402
-2,355
| -63% | -$6.55K | ﹤0.01% | 5729 |
|
|
2022
Q1 | $17K | Sell |
3,757
-5,303
| -59% | -$23.9K | ﹤0.01% | 5256 |
|
|
2021
Q4 | $62K | Buy |
9,060
+2,415
| +36% | +$16.5K | ﹤0.01% | 4964 |
|
|
2021
Q3 | $48K | Buy |
6,645
+708
| +12% | +$6.08K | ﹤0.01% | 4759 |
|
|
2021
Q2 | $59K | Buy |
5,937
+2,564
| +76% | +$23K | ﹤0.01% | 4740 |
|
|
2021
Q1 | $32K | Sell |
3,373
-1,032
| -23% | -$10.1K | ﹤0.01% | 4974 |
|
|
2020
Q4 | $48K | Buy |
4,405
+3,760
| +583% | +$39.6K | ﹤0.01% | 6069 |
|
|
2020
Q3 | $6K | Buy |
+645
| New | +$7.34K | ﹤0.01% | 6944 |
|
Other funds holding PSTX
Citigroup's PSTX Position: Q1 2025 in Review
Citigroup sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 53,844 shares — an estimated $517K sold.
Citigroup first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $867K in Q4 2022. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Citigroup reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Citigroup sold 53,844 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $517K.
- Citigroup first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Citigroup's Poseida Therapeutics, Inc. Common Stock position peaked at $867K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.